Eye Care A.I CyberSecurity Scoring
30/10/2025
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Eye Care in 2026.
No incidents recorded for Eye Care in 2026.
No incidents recorded for Eye Care in 2026.
Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.
Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.
This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement
We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/
A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA
We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms
Latest updates, reports, and threat intel affecting the global network.
Lucknow: To fast-track infrastructure and industrial growth in the state, Invest UP, in collaboration with NITI Aayog and key state...
Researchers have traced the threat activity to a newly identified hacker, while separate evidence points to more than one variant.
The HIPAA Journal has compiled healthcare data breach statistics from October 2009, when the Department of Health and Human Services (HHS)...
Cyberattacks have recently been announced by River City Eye in Oregon and Elmcrest Children's Center in New York. River City Eye Care River...
If you were affected by the River City Eye Care data breach, you may be entitled to compensation.
As an IT professional, you're likely concerned about cybersecurity and the implications of a ransomware attack…and for good reason.
NOVATO, Calif.—Zenni Optical announced it convened a panel this week called “Protect Your Eyes, Your Choice, Your Way,” bringing together...
A significant data breach at Retina Group of Florida has compromised the personal and medical information of nearly 153000 patients.
Lawmakers pressed Charles Worthington on data privacy and workforce readiness as the VA pushes ahead with AI.
Klever-Go is the Go implementation of the Klever blockchain protocol. Versions from 1.7.14 through 1.7.17 are vulnerable to a remotely triggerable denial of service. Both REST APIs are started with the Gin Engine.Run convenience method, which serves requests through Go's default HTTP server with no ReadHeaderTimeout, ReadTimeout, or MaxHeaderBytes configured. As a result, incoming connections that never complete their request headers are held open indefinitely. When a REST listener is reachable beyond localhost through the documented all-interface bind or a Docker port-publish deployment, a single unauthenticated client can open many slow-header connections and hold them open until server file descriptors are exhausted, preventing the API from accepting new connections. This renders the REST API unavailable to legitimate clients. This issue is fixed in version 1.7.18.
Klever-Go is the Go implementation of the Klever blockchain protocol. In versions 1.7.14 through 1.7.17, the direct-message ingress handler spawns a new goroutine for every incoming direct message before the processor-level antiflood layer makes any admission decision, with no semaphore, throttler, or bound on the number of concurrent in-flight spawns. Because the antiflood check runs inside the spawned goroutine rather than before it, a single connected peer can open a direct-send stream and send a stream of well-formed messages to force unbounded goroutine creation, where each goroutine allocates its own stack and holds a message reference until processing completes, adding scheduler and garbage-collection pressure faster than the runtime can drain it. This lets one peer degrade the node's availability and its ability to process legitimate traffic, resulting in a remotely triggerable denial of service. The issue is fixed in 1.7.18.
Klever-Go is the Go implementation of the Klever blockchain protocol. Versions 1.7.14 through 1.7.17 are vulnerable to a nil-pointer panic triggered by a protobuf Transaction whose embedded RawData sub-message is omitted. This omission causes RawData to decode to nil. Every transaction gossiped on the Klever-Go P2P network is decoded and validated synchronously inside the libp2p pubsub topic-validator callback, where txVersionChecker.CheckTxVersion dereferences tx.RawData.Version with no nil check. Because the libp2p pubsub callback, the underlying go-libp2p-pubsub validation worker, and Klever's own network/p2p layer install no recover(), the panic propagates and crashes the entire node process. The attacker payload is a 3-byte protobuf message; no validator key, stake, funds, or on-chain account is required, and delivery aimed at enough of the BLS validator set can halt block production, resulting in a chain halt. This issue has been fixed in version 1.7.18.
Klever-Go is the Go implementation of the Klever blockchain protocol. In versions prior to 1.7.18, the account-data trie syncers are vulnerable to a resource-exhaustion flaw that leaks bounded throttler slots on error paths. In syncDataTrie() (in both userAccountsSyncer.go and kappAccountsSyncer.go), StartProcessing() reserves a slot from the NumGoRoutinesThrottler, but the corresponding EndProcessing() is only called on the success path and on the duplicate-root early return. As a result, any error from trie.NewTrie(), trie.NewTrieSyncer(), or trieSyncer.StartSyncing() (including the network-dependent timeout path) permanently consumes one slot for the lifetime of the throttler. An attacker who can repeatedly cause trie-node sync failures or timeouts during bootstrap can exhaust the bounded throttler, after which further account-data trie syncs stop making progress and SyncAccounts() returns a timeout. Because epoch bootstrap in syncUserAccountsState() and syncKappAccountsState() aborts on any such error, this causes bootstrap to fail, a core availability issue affecting fresh, restarting, or resyncing nodes and validators. This issue is fixed in version 1.7.18.
Ruby LSP is an implementation of the language server protocol for Ruby. Several workspace-level settings in the Ruby LSP VS Code extension prior to version 0.10.4 could override the path to the Ruby executable, the version manager executables, or the Bundler `Gemfile` used at startup. A malicious repository containing a `.vscode/settings.json` could set these values to attacker-controlled targets. Opening and trusting the repository would then execute code with the privileges of the developer. The Ruby LSP gem and clients of the language server in other editors are not affected. Version 0.10.4 of the Ruby LSP VS Code extension fixes the issue.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.